Previous 10 | Next 10 |
Viela Bio Wins FDA Approval for Autoimmune Treatment Viela Bio ( VIE ) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that near...
On April 20th, Exelixis (EXEL) announced positive results from the Phase 3 trial, CheckMate-9ER, evaluating the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) for the first-line treatment of advanced/metastatic renal cell carcinoma ("RCC"). The stock increased by roughly 40% ...
Exelixis (NASDAQ: EXEL ) initiates a Phase 3 clinical trial, CONTACT-01, evaluating the combination of Cabometyx (cabozantinib) and Roche's Tecentriq (atezolizumab) in patients with metastatic non-small cell lung cancer who have been previously treated with an immune checkpoint inhibitor n...
– Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of three phase 3 pivotal trials that are part of a previously announced clinical collaboration with Roche – Exelixis, Inc. (NASDAQ: EXEL) ...
Exelixis Inc (EXEL) Goldman Sachs Global Healthcare Conference June 10, 2020 2:10 PM ET Company Participants Michael Morrissey - President & CEO Conference Call Participants Paul Choi - Goldman Sachs Presentation Paul Choi Okay. Good afternoon, everyone. We'll ...
Investment Thesis Exelixis 1-year share price performance. Source: TradingView . Exelixis ( EXEL ) stock surged 61% in late April to a price of $26.3 on news that its flagship drug, the tyrosine kinase inhibitor ("TKI") Cabozantinib, had met its primary endpoint in a combination trial alo...
In this episode of Industry Focus: Wildcard , Dylan Lewis chats with Motley Fool contributor Brian Feroldi about valuable lessons from a company working on a COVID-19 vaccine, the various clinical trial phases a drug has to undergo, how biotech companies generate revenues, how they are valued...
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June: William Blair 40 th Annual Growth Stock ...
The following slide deck was published by Exelixis, Inc. in conjunction with this Read more ...
– Data from three cohorts of phase 1b COSMIC-021 trial to be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) – – 27% objective response rate seen in immune checkpoint inhibitor-pretreated non-small cell lung ca...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...